Ключові слова
Ингибиторы протонной помпы, стандартные/высокие дозы, эрадикация Hр, гастроэзофагеальная рефлюксная болезнь.
Як цитувати
Kulakova, V. (2013). Клиническая польза высоких доз ингибиторов протонной помпы. Практикуючий лікар, (3), 23-24. вилучено із https://plr.com.ua/index.php/journal/article/view/431
Анотація
В статье подан обзор литературы, в котором показано, что подход к увеличению дозы ингибитора протонной помпы (ИПП) при эрадикации Helicobacter рylori (Нр) может быть более эффективным. Приведены результаты собственных наблюдений по ведению пациентов с гастроэзофагеальной рефлюксной болезнью (ГЭРБ) двойными стандартными дозами омепразола (препарат Омез® 40 мг).
Посилання
1. Fuccio L., Minardi M.E., Zagari R.M., Grilli D., Magrini N., Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for
Helicobacter pylori eradication // Ann. Intern. Med. - 2007. - 147. - P. 553-562.
2. Ford A., Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? // Can. J. Gastroenterol. - 2003. - 17(Suppl. B). - P. 36-40.
3. Calvet X., Garcia N., Lopez T., Gisbert J.P., Gene E., Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clari-thromycin and
either metronidazole or amoxycillin for treating Helicobacter pylori infection // Aliment. Pharmacol. Ther. - 2000. - 14. - P. 603-609.
4. Calvet X., Gene E., Lopez T., Gisbert J.P. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis
// Aliment. Pharmacol. Ther. - 2001. - 15. - P. 1067-1076.
5. Sugimoto M., Furuta T., Shirai N. et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple
therapy // Helicobacter. - 2007. - 12. - P. 317-323.
6. Labenz J., Beker J.A., Dekker C.P., Farley A., Klor H.U., Jonsson A. Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin
increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients // Aliment. Pharmacol. Ther. - 1997. - 11. - P. 515-522.
7. Vallve M., Vergara M., Gisbert J.P., Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a metaanalysis
// Aliment. Pharmacol. Ther. - 2002. - 16. - P. 1149-1156.
8. Horai Y., Kimura M., Furuie H. et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes // Aliment. Pharmacol.
Ther. - 2001. - 15. - P. 793-803.
9. Hunfeld N.G., Mathot R.A., Touw D.J. et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in
Caucasians // Br. J. Clin. Pharmacol. - 2008. - 65. - 752-760.
10. Katzka D.A., Paoletti V., Leite L., Castell D.O. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms:
testing while on therapy identifies the need for more aggressive anti-reflux therapy // Am. J. Gastroenterol.- 1996.- 91.- 2110-2113.
11. Mainie I., Tutuian R., Shay S. et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using
combined ambulatory impedance-pH monitoring // Gut.- 2006.- 55.- 1398-1402.
12. Padol S., Yuan Y., Thabane M., Padol I.T., Hunt R.H. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI
therapies: a meta-analysis // Am. J. Gastroenterol.- 2006.- 101.- 1467-1475.
13. Calvet X., Gomollon F. What is potent acid inhibition, and how can it be achieved? // Drugs 2005.- 65(Suppl. 1).- 13-23.
14. Villoria A., Garcia P., Calvet X. et al. Meta-analysis: high-dose proton pump inhibitors vs. Standard dose in triple therapy for Helicobacter pylori eradication
// Aliment. Pharmacol. Ther.- 2008.- 28.- 868–877.
15. Ткач С.М. Ведение больных гастроэзофагеальной болезнью в свете последнего американского консенсуса // Гастроэнтерология.- №2(48).-
2013.- С. 108-113.
Helicobacter pylori eradication // Ann. Intern. Med. - 2007. - 147. - P. 553-562.
2. Ford A., Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? // Can. J. Gastroenterol. - 2003. - 17(Suppl. B). - P. 36-40.
3. Calvet X., Garcia N., Lopez T., Gisbert J.P., Gene E., Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clari-thromycin and
either metronidazole or amoxycillin for treating Helicobacter pylori infection // Aliment. Pharmacol. Ther. - 2000. - 14. - P. 603-609.
4. Calvet X., Gene E., Lopez T., Gisbert J.P. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis
// Aliment. Pharmacol. Ther. - 2001. - 15. - P. 1067-1076.
5. Sugimoto M., Furuta T., Shirai N. et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple
therapy // Helicobacter. - 2007. - 12. - P. 317-323.
6. Labenz J., Beker J.A., Dekker C.P., Farley A., Klor H.U., Jonsson A. Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin
increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients // Aliment. Pharmacol. Ther. - 1997. - 11. - P. 515-522.
7. Vallve M., Vergara M., Gisbert J.P., Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a metaanalysis
// Aliment. Pharmacol. Ther. - 2002. - 16. - P. 1149-1156.
8. Horai Y., Kimura M., Furuie H. et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes // Aliment. Pharmacol.
Ther. - 2001. - 15. - P. 793-803.
9. Hunfeld N.G., Mathot R.A., Touw D.J. et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in
Caucasians // Br. J. Clin. Pharmacol. - 2008. - 65. - 752-760.
10. Katzka D.A., Paoletti V., Leite L., Castell D.O. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms:
testing while on therapy identifies the need for more aggressive anti-reflux therapy // Am. J. Gastroenterol.- 1996.- 91.- 2110-2113.
11. Mainie I., Tutuian R., Shay S. et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using
combined ambulatory impedance-pH monitoring // Gut.- 2006.- 55.- 1398-1402.
12. Padol S., Yuan Y., Thabane M., Padol I.T., Hunt R.H. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI
therapies: a meta-analysis // Am. J. Gastroenterol.- 2006.- 101.- 1467-1475.
13. Calvet X., Gomollon F. What is potent acid inhibition, and how can it be achieved? // Drugs 2005.- 65(Suppl. 1).- 13-23.
14. Villoria A., Garcia P., Calvet X. et al. Meta-analysis: high-dose proton pump inhibitors vs. Standard dose in triple therapy for Helicobacter pylori eradication
// Aliment. Pharmacol. Ther.- 2008.- 28.- 868–877.
15. Ткач С.М. Ведение больных гастроэзофагеальной болезнью в свете последнего американского консенсуса // Гастроэнтерология.- №2(48).-
2013.- С. 108-113.
Завантаження
Дані завантаження ще не доступні.